Next Article in Journal
Phylogeny and Evolution of Cocconeiopsis (Cocconeidaceae) as Revealed by Complete Chloroplast and Mitochondrial Genomes
Previous Article in Journal
Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host’s Immunity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 1
10.3390/ijms25010269
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer

by
Małgorzata Lasota
1,2,*,
Daniel Jankowski
2,3,
Anna Wiśniewska
4,
Michał Sarna
5,
Marta Kaczor-Kamińska
1,
Anna Misterka
1,2,
Mateusz Szczepaniak
2,5,
Joanna Dulińska-Litewka
1 and
Andrzej Górecki
3
1
Chair of Medical Biochemistry, Jagiellonian University Medical College, Kopernika 7, 31-034 Krakow, Poland
2
SSG of Targeted Therapy and Supramolecular Systems, Jagiellonian University Medical College, Kopernika 7, 31-034 Krakow, Poland
3
Department of Physical Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland
4
Chair of Pharmacology, Faculty of Medicine, Jagiellonian University Medical College, Grzegórzecka 16, 31-531 Krakow, Poland
5
Department of Biophysics, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387 Krakow, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(1), 269; https://doi.org/10.3390/ijms25010269
Submission received: 7 November 2023 / Revised: 15 December 2023 / Accepted: 21 December 2023 / Published: 23 December 2023
(This article belongs to the Section Molecular Oncology)
Browse Figures
Versions Notes

Abstract

Bladder cancer is a common malignancy associated with high recurrence rates and potential progression to invasive forms. Sorafenib, a multi-targeted tyrosine kinase inhibitor, has shown promise in anti-cancer therapy, but its cytotoxicity to normal cells and aggregation in solution limits its clinical application. To address these challenges, we investigated the formation of supramolecular aggregates of sorafenib with Congo red (CR), a bis-azo dye known for its supramolecular interaction. We analyzed different mole ratios of CR-sorafenib aggregates and evaluated their effects on bladder cancer cells of varying levels of malignancy. In addition, we also evaluated the effect of the test compounds on normal uroepithelial cells. Our results demonstrated that sorafenib inhibits the proliferation of bladder cancer cells and induces apoptosis in a dose-dependent manner. However, high concentrations of sorafenib also showed cytotoxicity to normal uroepithelial cells. In contrast, the CR-BAY aggregates exhibited reduced cytotoxicity to normal cells while maintaining anti-cancer activity. The aggregates inhibited cancer cell migration and invasion, suggesting their potential for metastasis prevention. Dynamic light scattering and UV-VIS measurements confirmed the formation of stable co-aggregates with distinctive spectral properties. These CR-sorafenib aggregates may provide a promising approach to targeted therapy with reduced cytotoxicity and improved stability for drug delivery in bladder cancer treatment. This work shows that the drug-excipient aggregates proposed and described so far, as Congo red—sorafenib, can be a real step forward in anti-cancer therapies.
Keywords: bladder cancer; tyrosine kinases inhibitor; Congo red; personalized medicine; multidisciplinary treatment bladder cancer; tyrosine kinases inhibitor; Congo red; personalized medicine; multidisciplinary treatment

Share and Cite

MDPI and ACS Style

Lasota, M.; Jankowski, D.; Wiśniewska, A.; Sarna, M.; Kaczor-Kamińska, M.; Misterka, A.; Szczepaniak, M.; Dulińska-Litewka, J.; Górecki, A. The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer. Int. J. Mol. Sci. 2024, 25, 269. https://doi.org/10.3390/ijms25010269

AMA Style

Lasota M, Jankowski D, Wiśniewska A, Sarna M, Kaczor-Kamińska M, Misterka A, Szczepaniak M, Dulińska-Litewka J, Górecki A. The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer. International Journal of Molecular Sciences. 2024; 25(1):269. https://doi.org/10.3390/ijms25010269

Chicago/Turabian Style

Lasota, Małgorzata, Daniel Jankowski, Anna Wiśniewska, Michał Sarna, Marta Kaczor-Kamińska, Anna Misterka, Mateusz Szczepaniak, Joanna Dulińska-Litewka, and Andrzej Górecki. 2024. "The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer" International Journal of Molecular Sciences 25, no. 1: 269. https://doi.org/10.3390/ijms25010269

APA Style

Lasota, M., Jankowski, D., Wiśniewska, A., Sarna, M., Kaczor-Kamińska, M., Misterka, A., Szczepaniak, M., Dulińska-Litewka, J., & Górecki, A. (2024). The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer. International Journal of Molecular Sciences, 25(1), 269. https://doi.org/10.3390/ijms25010269

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop